- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06391190
Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer
April 25, 2024 updated by: RenJi Hospital
A Prospective Single Arm Trial of Concurrent Chemoradiotherapy (With Albumin-Bound Paclitaxel/Cisplatin) Followed by PD-1 Inhibitor in Locally Advanced Cervical Cancer
To explore the safety and efficacy of Albumin-Bound Paclitaxel/Platinum based concurrent chemoradiotherapy Followed by PD-1 inhibitor (Sintilimab) in locally advanced cervical cancer
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
Patients with pathologically confirmed locally advanced cervical cancer will be treated with concurrent chemoradiotherapy (weekly Albumin-Bound Paclitaxel and cisplatin), followed by Sintilimab 200mg q3w for 8 cycles.
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Shanghai, China, 200127
- Recruiting
- RenJi Hospital
-
Contact:
- Yongrui Bai, Dr
- Phone Number: +862168383459
- Email: baiyongrui@renji.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age between 18 and 75;
- Untreated patients with pathologically proven locally advanced cervical cancer;
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
Adequate hematological, renal and hepatic functions:
4.1 Hemoglobin > 8.0 g/dl 4.2 Neutrophils > 2000 cells/μl; Leukocytes > 4 × 109/L 4.3 Platelets > 100 × 109/Lg. 4.4 Serum urea nitrogen (BUN) ≤ 1.5 × upper normal limit (UNL) 4.5 Serum creatinine (Cr) ≤ 1.5 × upper normal limit (UNL) 4.6 Serum ALT/AST ≤ 2.5× UNL 4.7 Serum Total bilirubin ≤ 1.5× UNL
- Life expectancy > 6 months
- Eligible for concurrent chemoradiotherapy assessed by principle investigator;
- No obvious active bleeding;
- Written informed consent must be available before study registration.
Exclusion Criteria:
- Recurrent or distant metastatic disease;
- Prior malignancies (other than curable non-melanoma skin cancer) within 5 years;
- Active autoimmune diseases requiring systemic treatment or other diseases requiring long-term use of substantial amount of hormones or other immunosuppressants;
- Patients who need to receive systemic corticosteroids (dose equivalent to or higher than prednisone 10mg qd) or other immunosuppressants within 14 days before enrollment or during the study;
- Vaccination of live attenuated vaccine 30 days before enrollment, or planned vaccination of live attenuated vaccine during the study;
- Previous organ transplantation or HIV patients;
- Allergic to macromolecular proteins /monoclonal antibodies, or to any test drug component;
- Active acute or chronic viral hepatitis B or C. Hepatitis B virus (HBV) DNA> 2000IU/ml or 104 copies/ml; hepatitis C virus (HCV) RNA> 103 copies/ml.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: treatment arm
with Albumin-Bound Paclitaxel 50-75mg/m2, cisplatin 25-40 mg/m2 weekly for up to 5 cycles during radical radiation (EBRT followed by brachytherapy); followed by Sintilimab 200mg Q3W for 8 cycles.
|
with Albumin-Bound Paclitaxel 50-75mg/m2, cisplatin 25-40 mg/m2 weekly for up to 5 cycles during radical radiation; followed by Sintilimab 200mg Q3W for 8 cycles
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
progression disease free survival
Time Frame: -2 years
|
the time interval from the date of treatment to disease progression, local or distant recurrence.
|
-2 years
|
safety of Albumin-Bound Paclitaxel/cisplatin based concurrent chemoradiotherapy followed by Sintilimab
Time Frame: -1 years
|
the occurrence and grade of side effect from treatment according to the CTCAE 4.0 and NCCN clinical practice guidelines in the evaluation treatment-related toxicity (through the symptoms, physical examination, and also through blood/image/encoscopy examination, such as blood routine, liver and renal function, TSH/T3/T4/ACTH concentration, myocardial enzymes, and EKG, echocardiography, CT, et al).
|
-1 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: 3 months
|
the percentage of the participants in the population who have a Complete Response or Partial Response accordingly to RECIST 1.1
|
3 months
|
distant-metastasis free survival
Time Frame: -2 years
|
the time interval from the date of treatment to distant recurrence.
|
-2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2022
Primary Completion (Estimated)
December 30, 2024
Study Completion (Estimated)
December 30, 2026
Study Registration Dates
First Submitted
April 25, 2024
First Submitted That Met QC Criteria
April 25, 2024
First Posted (Actual)
April 30, 2024
Study Record Updates
Last Update Posted (Actual)
April 30, 2024
Last Update Submitted That Met QC Criteria
April 25, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Uterine Cervical Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Albumin-Bound Paclitaxel
Other Study ID Numbers
- ACCI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immunotherapy
-
Ajou University School of MedicineCompletedImmunotherapyKorea, Republic of
-
The First Affiliated Hospital with Nanjing Medical...Recruiting
-
Centre Georges Francois LeclercAstraZenecaActive, not recruiting
-
Power Life Sciences Inc.Not yet recruitingCancer | Immunotherapy
-
Xuanwu Hospital, BeijingRecruitingImmunotherapy | ADRChina
-
Rutgers, The State University of New JerseyPfizer; American Cancer Society, Inc.CompletedImmunotherapy | Clinical TrialsUnited States
-
Peking University First HospitalYiZhou International Cancer HospitalUnknownImmunotherapy | Proton Therapy
-
Peking University First HospitalNot yet recruitingImmunotherapy | SBRT | Bulky Tumor
-
Nanfang Hospital, Southern Medical UniversityRecruitingImmunotherapy | Biomarker | HyperprogressionChina
Clinical Trials on Albumin-Bound Paclitaxel, cisplatin, Sintilimab
-
Qilu Hospital of Shandong UniversityWithdrawn
-
Peking UniversityNot yet recruitingThoracic Esophageal Squamous Cell CarcinomaChina
-
Sun Yat-sen UniversityInnovent Biologics (Suzhou) Co. Ltd.; CSPC Pharmaceutical Group LimitedCompletedEfficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC PatientsEsophageal Squamous Cell CarcinomaChina
-
Tongji HospitalZhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaboratorsNot yet recruitingCervical Cancer | Locally Advanced Cervical Cancer | PD-L1 Negative | Neoadjuvant ChemoimmunotherapyChina
-
Sichuan Cancer Hospital and Research InstituteFirst Affiliated Hospital Xi'an Jiaotong University; General Hospital of Ningxia... and other collaboratorsUnknownLocally Advanced Esophageal Squamous Cell CarcinomaChina
-
Tongji HospitalZhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaboratorsNot yet recruitingCervical Cancer | Fertility Preservation | Radical Hysterectomy | Neoadjuvant ChemoimmunotherapyChina
-
Huazhong University of Science and TechnologyChongqing University Cancer Hospital; Peking University People's Hospital; Qilu... and other collaboratorsRecruitingCervical Cancer | Uterine Cervical Cancer | Uterine Cervical NeoplasmChina
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
Tang-Du HospitalRecruitingNon Small Cell Lung CancerChina
-
Nanfang Hospital, Southern Medical UniversityNot yet recruitingNeoadjuvant Therapy | Esophageal Carcinoma